Association between response to triptans and response to erenumab: real-life data

Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives

(2020) Eleonora De Matteis et al.   Expert Review of Neurotherapeutics

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

(2020) Raffaele Ornello et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study

(2020) Bianca Raffaelli et al.   Frontiers in Neurology

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review

(2020) Rami Burstein et al.   HEADACHE

Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience

(2020) Antonio Russo et al.   JOURNAL OF HEADACHE AND PAIN

A prospective real-world analysis of erenumab in refractory chronic migraine

(2020) Giorgio Lambru et al.   JOURNAL OF HEADACHE AND PAIN

Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients

(2020) Ozan E. Eren et al.   Scientific Reports

Real-world effectiveness and tolerability of erenumab: A retrospective cohort study

(2020) Saad Kanaan et al.   CEPHALALGIA

Erenumab in Chronic Migraine: An Australian Experience

(2020) Shuli Cheng et al.   HEADACHE

Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center

(2020) Eleonora Matteo et al.   NEUROLOGICAL SCIENCES

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

(2019) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab: from scientific evidence to clinical practice—the first Italian real-life data

(2019) Piero Barbanti et al.   NEUROLOGICAL SCIENCES

How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice

(2019) Cindy Tiseo et al.   JOURNAL OF HEADACHE AND PAIN

Migraine and the trigeminovascular system—40 years and counting

(2019) Messoud Ashina et al.   LANCET NEUROLOGY

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

May migraine attack response to triptans be a predictor of the efficacy of Onabotulinum toxin-A prophylaxis?

(2018) Carlo Lovati et al.   NEUROLOGICAL SCIENCES

Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2018) Lars Jacob Stovner et al.   LANCET NEUROLOGY

The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine

(2017) Lars Edvinsson   HEADACHE

Fremanezumab - a humanized monoclonal anti-CGRP antibody — inhibits thinly myelinated (Aδ) but not unmyelinated (C) meningeal nociceptors

(2017) Agustin Melo-Carrillo et al.   JOURNAL OF NEUROSCIENCE

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains

(2014) Rami Burstein et al.   CEPHALALGIA